HIGH-AFFINITY INTERLEUKIN-4 MUTEINS
    24.
    发明授权
    HIGH-AFFINITY INTERLEUKIN-4 MUTEINS 失效
    白细胞介素-4突变蛋白高亲和力

    公开(公告)号:EP0939817B1

    公开(公告)日:2005-11-23

    申请号:EP97933333.3

    申请日:1997-07-09

    申请人: BAYER CORPORATION

    摘要: A recombinant human IL-4 mutein numbered in accordance with wild-type IL-4 wherein the mutein comprises at least one amino acid substitution in the binding surface of either the A- or C-alpha helices of the wild-type IL-4 whereby the mutein binds to the IL-4R alpha receptor with at least greater affinity than native IL-4. The substitution is more preferably selected from the group of positions consisting of, in the A-helix, positions 13 and 16, and in the C-helix, positions 81 and 89. A most preferred embodiment is the recombinant human IL-4 mutein wherein the substitution at position 13 is Thr to Asp. Pharmaceutical compositions, amino acid and polynucleotide sequences encoding the muteins, transformed host cells, antibodies to the muteins, and methods of treatment are also described.

    T-CELL SELECTIVE INTERLEUKIN-4 AGONISTS
    26.
    发明授权
    T-CELL SELECTIVE INTERLEUKIN-4 AGONISTS 失效
    T细胞选择性白细胞介素-4 AGONISTE

    公开(公告)号:EP0912741B1

    公开(公告)日:2004-07-28

    申请号:EP97927864.5

    申请日:1997-05-30

    申请人: Bayer Corporation

    摘要: The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T-cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T-cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R121I, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild-type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.